Steve Chen

Effects of pramlintide in patients with type 2 diabetes mellitus: an analysis using daily insulin dose tertiles.

S. Brunell, K. Herrmann, K. Shan, 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Once-Weekly Glucose-Lowering Therapy for Type 2 Diabetes

M. Deyoung, A. Blickensderfer, Steve Chen, 2012, Clinical Diabetes.

Optimizing the Clinical Use of the GLP-1 Receptor Agonist Exenatide Once Weekly

S. Brunell, M. Deyoung, E. Bezarro, 2013, Diabetes Spectrum.

Effect of Ljpc-401 (synthetic human hepcidin) on Iron Parameters in Healthy Adults

K. Kowdley, A. Taher, L. Chawla, 2018, Blood.

Exenatide is Non-inferior to Insulin in Reducing HbA1c: An Integrated Analysis of 1423 Patients with Type 2 Diabetes

S. Aronoff, T. Blevins, Juliana H. Oliveira, 2010, Postgraduate medicine.

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes

M. Stolar, M. Grimm, Steve Chen, 2013, Diabetes, metabolic syndrome and obesity : targets and therapy.

Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes mellitus requiring insulin intensification—a randomized phase IV trial: Indian subpopulation analyses

Shweta Uppal, Sanjiv Shah, P. Shah, 2017, International Journal of Diabetes in Developing Countries.

Pramlintide Improved Measures of Glycemic Control and Body Weight in Patients With Type I Diabetes Mellitus Undergoing Continuous Subcutaneous Insulin Infusion Therapy

J. Frias, S. Edelman, D. Maggs, 2013, Postgraduate medicine.

Increased variability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjects with type 2 diabetes

J. Malloy, P. Yan, Kate Gurney, 2012, Diabetes, metabolic syndrome and obesity : targets and therapy.